12 July 2024 -  Onco360 has been selected as a pharmacy partner by Geron Corporation for Rytelo (imetelstat) as a first in class oral, oligonucleotide telomerase inhibitor, approved for the treatment of adult patients with low to intermediate risk myelodysplastic syndromes with transfusion dependent anaemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.

Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company.

Read Onco360 press release